Revenue
2021
2022
2023
2024
2025
Verrica Pharmaceuticals Inc. (VRCA)
Price$5.30Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.6M | $7.6M | $5.1M | $9.0M | $12.0M | — | — | — | — |
| Gross profit | $32.1M | $5.0M | $4.6M | $8.3M | — | — | — | — | — |
| Gross margin | 90.33% | 65.64% | 90.24% | 91.97% | — | — | — | — | — |
| Research & development | $8.9M | $11.8M | $20.3M | $12.2M | $15.9M | $15.7M | $15.4M | $12.8M | $3.7M |
| Operating expenses | $47.8M | $73.5M | $70.9M | $30.3M | $42.9M | $40.2M | $30.1M | $21.9M | $4.5M |
| Operating income | −$12.2M | −$65.9M | −$65.8M | −$21.3M | −$30.9M | −$40.2M | −$30.1M | −$21.9M | −$4.5M |
| Operating margin | −34.25% | −871.25% | −1,283.35% | −235.78% | −257.57% | — | — | — | — |
| EBITDA | −$11.7M | −$65.0M | −$65.2M | −$20.8M | −$30.7M | −$40.1M | −$30.0M | −$21.9M | — |
| EBITDA margin | −32.89% | −858.55% | −1,272.62% | −230.76% | −255.49% | — | — | — | — |
| Net income | −$17.9M | −$76.6M | −$67.0M | −$24.5M | −$35.1M | −$42.7M | −$28.2M | −$20.6M | −$4.5M |
| Net profit margin | −50.27% | −1,012.15% | −1,307.47% | −271.11% | −292.33% | — | — | — | — |
| Basic EPSper basic share | -$1.68 | -$14.78 | -$14.80 | -$7.20 | -$13.00 | -$17.10 | -$11.30 | -$14.10 | -$15.60 |
| Diluted EPSper diluted share | -$1.68 | -$14.78 | -$14.80 | -$7.20 | -$13.00 | -$17.10 | -$11.30 | -$14.10 | -$15.60 |
Owners
Reported shareholders
≈19.49%of listed shares
BKB Growth Investments, LLC3.35M shares · Nov 25, 2025
View holders
| Holder | % owned |
|---|---|
BKB Growth Investments, LLC | ≈19.49%3.35M shares |
Stalfort John A III | ≈10.91%1.87M shares |
Caligan Partners LP | 5.38%923.91K shares |
CANNELL CAPITAL LLC | 4.56%783.92K shares |
Affinity Asset Advisors, LLC | 4.12%707.34K shares |
Velan Capital Investment Management LP | 2.75%471.56K shares |
ARMISTICE CAPITAL, LLC | 2.48%426.3K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 1.63%280.73K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.63%279.31K shares |
White Ted | ≈1.26%215.97K shares |
Mariner, LLC | 1.21%207.23K shares |
Rieger Jayson | —182.84K shares |
Hayes Christopher G. | ≈1.03%176.46K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.80%138.16K shares |
Goldenberg Gary | ≈0.55%94.26K shares |
BlackRock, Inc. | 0.43%74.34K shares |
Bonaccorso Joe | ≈0.43%73.11K shares |
VANGUARD FIDUCIARY TRUST CO | 0.41%70.17K shares |
Kohler Terry | ≈0.26%44.7K shares |
TWO SIGMA INVESTMENTS, LP | 0.24%40.83K shares |
Percentages use 17.18M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 25, 2025Form 4 | Zawitz DavidChief Operating Officer | BuyCommon Stock | 10.0K | $4.24 | $42.4K | 21.0K |
| Nov 25, 2025Form 4 | Zawitz DavidChief Operating Officer | BuySeries C Warrant (right to buy) · derivative | 2.5K | — | — | 2.5K |
| Nov 25, 2025Form 4 | Rieger JaysonCEO and President | BuyCommon Stock | 94.3K | $4.24 | $399.9K | 182.6K |
| Nov 25, 2025Form 4 | Rieger JaysonCEO and President | BuySeries C Warrant (right to buy) · derivative | 23.6K | — | — | 23.6K |
| Nov 25, 2025Form 4 | Rosenberg Noah L.CMO | BuyCommon Stock | 2.4K | $4.24 | $10.0K | 2.4K |